WALTER FERLIN

Company: Light chain Biosciences

Job title: Chief Scientific Officer & Head of Exploratory Science & Translational Medicine Department

Seminars:

Eliciting Potent & Safe Innate & Adaptive Immune Responses to Cancer with Bispecific Antibody Approaches to CD47 or CD28 4:45 pm

Bispecific antibodies (bsAbs) were developed to selectively target CD47 on tumor cells and regulate CD28-mediated T-cell co-stimulation, overcoming tolerability challenges encountered with monoclonal antibody (mAb) approaches while avoiding systemic toxicities associated with CD47 and CD28 targeting, respectively CD47bsAbs with fully competent IgG1-Fc domains show potent anti-tumor activity in vitro and in vivo, prompting human trials…Read more

day: Day One